The Oncology Institute, Inc. (TOI): Price and Financial Metrics
TOI Price/Volume Stats
Current price | $1.56 | 52-week high | $2.66 |
Prev. close | $1.84 | 52-week low | $0.33 |
Day low | $1.51 | Volume | 200,535 |
Day high | $1.78 | Avg. volume | 134,252 |
50-day MA | $1.86 | Dividend yield | N/A |
200-day MA | $1.49 | Market Cap | 114.96M |
TOI Stock Price Chart Interactive Chart >
TOI POWR Grades
- TOI scores best on the Sentiment dimension, with a Sentiment rank ahead of 93.5% of US stocks.
- The strongest trend for TOI is in Growth, which has been heading up over the past 26 weeks.
- TOI ranks lowest in Quality; there it ranks in the 8th percentile.
TOI Stock Summary
- With a one year PEG ratio of 0.01, ONCOLOGY INSTITUTE INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 0.4% of US stocks.
- In terms of twelve month growth in earnings before interest and taxes, ONCOLOGY INSTITUTE INC is reporting a growth rate of -18,587.71%; that's higher than merely 0.07% of US stocks.
- In terms of volatility of its share price, TOI is more volatile than 93.84% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to ONCOLOGY INSTITUTE INC, a group of peers worth examining would be RAND, WYNN, XPOF, ALL, and CLMT.
- To check out ONCOLOGY INSTITUTE INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001799191.
TOI Valuation Summary
- In comparison to the median Healthcare stock, TOI's price/sales ratio is 77.27% lower, now standing at 0.5.
- Over the past 46 months, TOI's price/sales ratio has gone down 1.4.
Below are key valuation metrics over time for TOI.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
TOI | 2023-12-29 | 0.5 | 2.1 | -2.0 | -3.7 |
TOI | 2023-12-28 | 0.5 | 2.2 | -2.1 | -3.8 |
TOI | 2023-12-27 | 0.5 | 2.1 | -2.0 | -3.7 |
TOI | 2023-12-26 | 0.5 | 2.1 | -2.0 | -3.7 |
TOI | 2023-12-22 | 0.4 | 1.8 | -1.7 | -3.4 |
TOI | 2023-12-21 | 0.4 | 1.7 | -1.7 | -3.3 |
The Oncology Institute, Inc. (TOI) Company Bio
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, outpatient stem cell transplants and transfusions programs, and 24/7 patient support. The company was founded in 2007 and is headquartered in Cerritos, California.
Latest TOI News From Around the Web
Below are the latest news stories about ONCOLOGY INSTITUTE INC that investors may wish to consider to help them evaluate TOI as an investment opportunity.
Insider Spends US$127k Buying More Shares In Oncology InstituteInvestors who take an interest in The Oncology Institute, Inc. ( NASDAQ:TOI ) should definitely note that the Chief... |
The Oncology Institute Expands its Specialty Medication Business by Opening Pharmacy Operations in CaliforniaCERRITOS, Calif, Dec. 04, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (TOI) announced today that it has started operations of its first pharmacy in California after receiving approval from the California State Board of Pharmacy. This new service allows TOI to fill not only critical specialty medications and chemotherapeutics for MediCal patients, but also to provide medication fill capabilities to other patient populations. Located in the Los Angeles area, this new pharmacy location co |
Insider Sell Alert: Director Brad Hively Sells 47,000 Shares of The Oncology Institute Inc (TOI)In a notable insider transaction, Director Brad Hively has parted with 47,000 shares of The Oncology Institute Inc (NASDAQ:TOI), a significant move that warrants a closer look by investors and market analysts. |
Even With A 49% Surge, Cautious Investors Are Not Rewarding The Oncology Institute, Inc.'s (NASDAQ:TOI) Performance CompletelyDespite an already strong run, The Oncology Institute, Inc. ( NASDAQ:TOI ) shares have been powering on, with a gain of... |
The Oncology Institute Inc (TOI) Reports Q3 2023 Results: Revenue Up, Net Loss WidensTOI Reaffirms Full Year 2023 Guidance Amidst Expansion and Operational Developments |
TOI Price Returns
1-mo | -18.32% |
3-mo | -23.53% |
6-mo | 11.43% |
1-year | 131.25% |
3-year | N/A |
5-year | N/A |
YTD | -23.53% |
2023 | 23.64% |
2022 | -83.08% |
2021 | -9.72% |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...